Small Cap Feast
Small Cap Feast – 12 July 2019
Dish of the Day:
Off the Menu:
What’s Cooking in the IPO Kitchen?
Faron Pharmaceuticals (AEG.L) 0.41p £4.81m
Faron Pharmaceuticals, the clinical stage biopharmaceutical company, today announced additional data from the open label phase I/II MATINS clinical trial investigating the safety and efficacy of Clevegen, Faron’s wholly-owned novel precision cancer immunotherapy, in selected metastatic or inoperable solid tumours.
“We are thrilled with the progress the MATINS study has made during the last few months. We believe we have the first macrophage immune checkpoint drug in clinical development promoting immune activation and are encouraged by the latest data indicating potential early efficacy and good tolerability. We expect to progress the cohort expansion phase of the study in Q3 2019 in patients with late-stage colorectal cancer and as more data are generated we will seek guidance from regulators regarding the best and fastest pathway to secure initial approval of Clevegen as a single-agent treatment.
“We also hope to conclude partnering discussions during H2-2019, which should enable us to expand clinical development to include combination studies exploring the potential of Clevegen in combination with existing immunotherapies.”
Anglo African Oil & Gas (AAOG.L) 4.44p £10.59m
Further to the announcements of 3 July and 8 July the Company announces that the board has unanimously decided to progress financing discussions with co-investors Riverfort Global Capital Limited and Yorkville Advisors. This follows a competitive process in which three potential investors who had indicated interest were asked to provide their best and final offers to the Company. These offers were reviewed by a sub-committee of the board led by the Non-Executive Directors which led to the choice of Riverfort and Yorkville as preferred providers.
The Company will now look to finalise a definitive equity sharing agreement with Riverfort and Yorkville. The Company expects to be able to announce that the final terms are preferable for the Company compared to those previously announced.
In the meantime, the Company confirms that the major investor in the Placing (subscribing for 49,288,347 shares (£2,562,994 at a price of 5.2p per share)), as announced on 3 July 2019, has reconfirmed its commitment to that investment.
Audioboom (BOOM.L) 255.00p £32.86m
Audioboom, the leading global podcast company, announces that it has opened two new recording studios, comprising over 1,000 sq. ft. of recording and production space, within its existing office in New York City, USA.
Due to significant and growing demand for roundtable and personality driven podcasts, Audioboom has expanded its production operation with the launch of a 1,000 sq. ft. studio complex in midtown Manhattan comprising two new recording studios and a new Green Room for talent. One of the new studios will serve Audioboom’s roundtable and personality driven shows, while the other will be dedicated to more intimate, interview style shows and solo productions.
The new studios will assist Audioboom with launching new Audioboom Originals Network podcasts in 2019, including: Never Thought I’d Say This with Fuller House Star Jodie Sweetin, a biological podcast A Life Lived, and movie show Truth vs. Hollywood. The new studios will also reduce the costs associated with renting/leasing third party studios for in-house productions such as: Mafia, Covert, Nightcall, Blank Check, and It’s Happening with Snooki and Joey.
Renalytix AI (RENX.L) 329.00p £177m
Renalytix AI, a developer of artificial intelligence enabled clinical diagnostics for kidney disease, welcomes the Executive Order signed by the President of the United States of America on 10 July 2019 to launch Advancing American Kidney Health, a new initiative to improve the lives of Americans suffering from kidney disease, expand options for American patients, and reduce healthcare costs.
The Executive Order sets out the policy of the United States to prevent kidney failure whenever possible through better diagnosis, treatment and incentives for preventative care. The Secretary of Health and Human Services is expected to launch an awareness initiative to educate patients and support programmes that promote kidney disease awareness. In addition, the Secretary will select a payment model to identify and treat at-risk populations earlier in disease development. The model should broaden the range of care and Medicare payment options available to potential participants with a focus on delaying or preventing the onset of kidney failure, preventing unnecessary hospitalisations, and increasing the rate of transplants.
Vela Technologies plc(VELA.L) 0.125p £1.18m
The Board of Vela notes the announcement by Interbit Ltd (“Interbit”) (formerly called BTL Group Ltd) on 11 July 2019 regarding its product strategy and a contract with Xinova, LLC.
Vela owns 620,000 common shares in Interbit equivalent to approximately 2.6 per cent. of Interbit’s issued share capital. Interbit is listed on the TSX Venture Exchange, on which the opening mid-market price on 11 July 2019 was C$0.70 per share. This values Vela’s shareholding in Interbit at C$434,000 (equivalent to c. £264,527*).
Shearwater Group plc(SWG.L) 1.865p £40.5m
Shearwater Group, the organisational resilience group, announced that its group company Brookcourt Solutions has won a contract to supply and deploy cyber security software and services in a multi-year agreement worth £0.5m in aggregate to Deloitte ES Cyber Risk Services covering the EMEA region.
Under the terms of the contract, Brookcourt Solutions will be managing the project on behalf of Deloitte and working with the vendor to provide the threat intelligence software and associated cyber security services.
Science Group plc (SAG.L) 199p £81.84m
Science Group plc announced that on 11 July 2019 the Company purchased 2,433,648 shares in the capital of Frontier at a price of 35p per share. Following these purchases, the Company holds a total of 14,577,934 shares in the capital of Frontier, equivalent to 35.8%% of the voting share capital of Frontier.
Tremor International (TRMR.L) 121p £148.78m
Tremor, a global leader in advertising technologies for brand advertising and performance-based mobile marketing, announced that on 11 July 2019 it bought-back 110,000 ordinary shares of NIS0.01 each in the capital of the Company in the market at a price of 121p per Ordinary Share. The Ordinary Shares acquired pursuant to the Buyback Programme will be reclassified as dormant shares under the Israeli Companies Law (without any rights attached thereon) and will be held in treasury.
Trans-Siberian Gold (TSG.L) 81.77p £87.12m
Trans-Siberian Gold, a low cost, high grade gold producer in Russia, announced the appointment of Sergey Kryazhevskih as CFO, with immediate effect. The composition of the Board is unchanged.
Mr Kryazhevskih has over fifteen years of experience in the mining industry, most recently serving as CFO of JSC Pavlik, a Russian top 10 gold producer operating in Russia’s Far East. During his tenure at Pavlik, the Company successfully restructured its financial obligations in the amount of $750m. Prior to this, Sergey held senior positions at Atomredmetzoloto and Evraz, a FTSE 100 company, responsible for leading budgeting, investment planning and financial control.
Sergey has extensive experience in managing investor, community and senior government relations in Russia’s Far East.
Mr Kryazhevskih graduated from the Moscow State University (MSU) with a degree in Economics and holds a Masters degree from MSU in Management, majoring in accounting, financial analysis and audit.
CyanConnode Holdings (CYAN.L) 6.50p £11.04m
CyanConnode, a world leader in Narrowband Radio Frequency (RF) Smart Mesh Networks, announced that it has received a follow-on Nordic order worth €489,000.
The order, for legacy CyanConnode hardware and software, is from an existing Partner and the end customer is a Nordic Utility, who is expanding an existing smart metering deployment. The Company expects to recognise 50% of the revenues for this follow-on order in 2019 and 50% in 2020.
The existing smart metering deployment has been delivering reliable communications between consumers and the utility’s data collection centre for over eight years, thereby providing significant benefits, including improved information on energy consumption, simplified billing and enhanced customer service.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.